Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults

scientific article published on December 1, 2010

Tdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1023336379
P356DOI10.2165/11206000-000000000-00000
P698PubMed publication ID21043546

P50authorLesley J ScottQ62563724
P2860cites workEpidemiology of pertussisQ36118044
Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerationsQ36118110
Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccinationQ36148322
Economic considerations for pertussis booster vaccination in adolescentsQ36148334
P433issue6
P407language of work or nameEnglishQ1860
P921main subjectteenagerQ1492760
immunizationQ1415366
P304page(s)387-406
P577publication date2010-12-01
P1433published inBioDrugsQ4914612
P1476titleTdap5 vaccine (Covaxis): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged 4 years), adolescents, and adults
P478volume24

Reverse relations

cites work (P2860)
Q36849826Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries
Q34636630Pertussis re-emergence in the post-vaccination era
Q83477433Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults

Search more.